- Home
- CATX vs RDIB Comparison
CATX vs RDIB Comparison
Compare CATX & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- RDIB
- Stock Information
- Founded
- CATX 1983
- RDIB 1937
- Country
- CATX United States
- RDIB United States
- Employees
- CATX N/A
- RDIB N/A
- Industry
- CATX Medical/Dental Instruments
- RDIB Movies/Entertainment
- Sector
- CATX Health Care
- RDIB Consumer Discretionary
- Exchange
- CATX Nasdaq
- RDIB Nasdaq
- Market Cap
- CATX 133.3M
- RDIB 140.2M
- IPO Year
- CATX N/A
- RDIB N/A
- Fundamental
- Price
- CATX $1.94
- RDIB $10.00
- Analyst Decision
- CATX Strong Buy
- RDIB
- Analyst Count
- CATX 10
- RDIB 0
- Target Price
- CATX $13.89
- RDIB N/A
- AVG Volume (30 Days)
- CATX 950.5K
- RDIB 3.9K
- Earning Date
- CATX 05-12-2025
- RDIB 05-14-2025
- Dividend Yield
- CATX N/A
- RDIB N/A
- EPS Growth
- CATX N/A
- RDIB N/A
- EPS
- CATX N/A
- RDIB N/A
- Revenue
- CATX $1,454,000.00
- RDIB $210,527,000.00
- Revenue This Year
- CATX N/A
- RDIB $11.97
- Revenue Next Year
- CATX $1.15
- RDIB $6.40
- P/E Ratio
- CATX N/A
- RDIB N/A
- Revenue Growth
- CATX 1.40
- RDIB N/A
- 52 Week Low
- CATX $1.60
- RDIB $5.78
- 52 Week High
- CATX $19.10
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- CATX 41.33
- RDIB 70.61
- Support Level
- CATX $1.60
- RDIB $7.61
- Resistance Level
- CATX $2.11
- RDIB $9.30
- Average True Range (ATR)
- CATX 0.21
- RDIB 0.84
- MACD
- CATX 0.03
- RDIB 0.24
- Stochastic Oscillator
- CATX 55.74
- RDIB 100.00
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.